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Abstract
Small cell carcinoma of the anus is a very rare but aggressive tumour. We present a case of a 60-
year old lady with small cell carcinoma of the anus. She had no metastatic disease on presentation.
She had chemotherapy and radiotherapy but developed distant metastasis after completion of
treatment. Immunohistochemistry is required to make a diagnosis. Chemotherapy remains the
mainstay of treatment for small cell carcinoma of the anus with or without metastatic disease.
Radiotherapy is for local control and relief of symptoms.
Introduction
Anal cancer is a rare tumour of the gastrointestinal tract
representing only about 2% of the anorectal malignancies
[1]. Most common anal cancers are squamous cell carci-
nomas and adenocarcinomas. Less common ones are
basaloid carcinoma, melanoma, leiomyosarcoma and
small cell carcinoma [1]. The latter, though very rare, is
clinically important because of its aggressive clinical
course with a tendency for early distant metastases. Small
cell carcinomas of the anus are oncologically similar to
their counterparts in the lungs and are therefore treated
along the same lines.
Case presentation
A 60-year old African lady originally from Ghana pre-
sented with a short history of rectal bleeding and anal
pain. Over the past three months, she had noticed tenes-
mus and increased frequency of bowel movements, as
well as anorexia and weight loss. There was no significant
past or family history. She was a non-smoker. On rectal
examination there was a palpable mass which bled on
contact. There were no clinical features of bowel obstruc-
tion. An MRI of the anus showed a 2.7 cm tumour in the
posterior aspect of the distal anal canal (Figure 1). At
examination under anaesthetic (EUA) the mass in the
anus was confirmed and biopsies were taken. The histopa-
thology showed small malignant cells with hyperchro-
matic nuclei and scanty cytoplasm on haematoxylin and
eosin staining (Figure 2). On immunostaining, the malig-
nant cells were strongly positive for CD56 (Figure 3) and
showed weak focal positivity for CAM 5.2 and MNF. There
was negative staining for CK7, CK20, thyroid transcrip-
tion factor 1 (TTF-1) and leukocyte common antigen.
These results were consistent with a primary small cell car-
cinoma of the anus. The patient was not tested for HIV
and tumour markers were not measured. Staging CT and
PET scans showed no evidence of metastatic disease. The
patient underwent treatment with six cycles of chemother-
apy using cisplatinum and etoposide followed by a course
of radical radiotherapy to the anus and pelvis. Following
treatment there was thickening at the primary tumour site;
however two EUA's and biopsies did not show any resid-
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the patient relapsed with liver and lung metastasis
although the primary site remained clear. No response
was seen to palliative chemotherapy and the patient suc-
cumbed to metastatic disease 18 months following the
initial diagnosis.
Discussion
Small-cell carcinoma of the lungs, first described in 1926,
accounts for about 20% of all lung cancers whereas extra-
pulmonary small cell carcinomas are uncommon, with an
incidence of approximately 0.4% [2]. Approximately 544
cases of gastro-intestinal small cell carcinomas were
reported in the English literature till 2004 [3]. The
oesophagus is the most common primary site followed by
colorectal [4].
Less than 1% of anal cancers are small cell carcinomas-the
most common being squamous cell carcinomas (74%)
and 19% are adenocarcinomas [5].
These tumours have been documented in HIV positive
patients, and those with a history of exposure to radiation
[6]. Neuroendocrine (NE) tumours can be found inciden-
tally within adenomatous polyps [7,8]. To diagnose small
cell carcinoma, positive immuno-reactivity to neuroendo-
crine markers is required-the most reliable being synapto-
physin [9]. Other markers include CD56 and Leu-7/
CD57. CD56 is a neural cell adhesion molecule that is
positive in small cell carcinomas of different sites includ-
ing the lung and gastrointestinal tract. The use of thyroid
transcription factor (TTF)-1 will help separate a primary
anal canal small cell carcinoma from a lung metastasis, as
it is positive in the latter. Systemic symptoms are com-
mon; ectopic hormonal secretion may occur.
These tumours are highly aggressive, with lymph node,
liver and lung metastasis at presentation even when the
primary tumour is limited to the submucosa or mucosa
[10]. Metastatic disease was detected at the time of diag-
nosis in 69% percent of the patients in the study by Ber-
nick et al [9]. The 6-month survival is 58% and 5-year
survival is 6% [11]. In contrast, for squamous cell carci-
noma of the anus, the overall survival rate for advanced
tumours is 50-60% at 5 years [12]. In anal small cell car-
cinoma with or without metastatic disease at presenta-
MRI of the anal canal showing the tumourFigure 1
MRI of the anal canal showing the tumour.
Haematoxylin and eosin staining of the small cell carcinoma of the anusFigure 2
Haematoxylin and eosin staining of the small cell car-
cinoma of the anus.
Immunohistochemical staining of the small cell carcinoma of the anusFigure 3
Immunohistochemical staining of the small cell carci-
noma of the anus.Page 2 of 3
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tion, chemotherapy is the main modality of treatment. It
is Cisplatinum-based and usually includes etoposide,
cyclophosphamide and doxorubicin. Radiotherapy is
mainly for local control and relief of symptoms [1]. The
response to chemotherapy is 70% to 90% though tran-
sient. Typically, a good response to initial therapy is
shortly followed by relapse or rapid progression with a
median survival of only 6-12 months [1]. Though our
patient did not present with distant metastasis, she devel-
oped lung and liver secondaries a year after completion of
treatment. At this stage there was no local recurrence. Her
clinical course matched what has been described in previ-
ous case reports.
Conclusion
Small cell carcinoma of the anus is very rare. Immunocy-
tochemistry is needed for diagnosis. Chemotherapy is the
mainstay of treatment even though the response is short
lived. Radiotherapy is mainly for local control and relief
of symptoms. The prognosis is poor with frequent early
distant metastasis despite local control.
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